Adverse events258

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 258

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Anemia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	3	6	8
other	Anemia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	2	4	4
other	Hyperleukocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Hyperleukocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	1	6	1
other	Hyperleukocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	0	4	0
other	Lymphopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Lymphopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	0	6	0
other	Lymphopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	1	4	1
other	Thrombopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	1	3	2
other	Thrombopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	1	6	2
other	Thrombopenia	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	0	4	0
other	Thrombocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Thrombocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	1	6	1
other	Thrombocytosis	Blood and lymphatic system disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	0	4	0
other	Arteriospasm coronary	Cardiac disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Arteriospasm coronary	Cardiac disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	1	6	1
other	Arteriospasm coronary	Cardiac disorders	Experimental: Irinotecan 180 mg/m² (IV) and Regorafenib at 160 mg (PO)	0	4	0
other	Vertigo	Ear and labyrinth disorders	Experimental: Irinotecan 150 mg/m² (IV) and Regorafenib at 120 mg (PO)	0	3	0
other	Vertigo	Ear and labyrinth disorders	Experimental: Irinotecan 180 mg/m² (IV) Cand Regorafenib at 120 mg (PO)	0	6	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03828799/events

API reference For AI assistants

Adverse events258

Sources 3

Read this list from software.